University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2023

  1. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Leukemia, Vol. 37, Núm. 3, pp. 617-626

2022

  1. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

    Journal of Hematology and Oncology, Vol. 15, Núm. 1

  2. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S295-S296

  3. MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S326-S327

2021

  1. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Blood, Vol. 138, Núm. 21, pp. 2031-2041

2020

  1. Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis

    Blood Advances, Vol. 4, Núm. 22, pp. 5825-5835

2019

  1. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

    Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1589-1599

2018

  1. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial

    Journal of Clinical Oncology, Vol. 36, Núm. 3, pp. 231-237

2010

  1. Characteristics of pericardial effusions in patients with leukemia

    Cancer, Vol. 116, Núm. 10, pp. 2366-2371